TCR2 Therapeutics Encouraging Oncology Results

TCR2 Therapeutics Announcement

TCR2 Therapeutics (TCRR) – a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for cancer, announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients have demonstrated tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months.

The toxicity profile has been manageable and was observed only in one patient exhibiting TC-210-related non-hematologic grade >2 toxicity but no evidence of neurotoxicity or on-target, off-tumor toxicity.

Leave a Reply